Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
35,084
Total Claims
$5.8M
Drug Cost
1,846
Beneficiaries
$3,159
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
-20%
Cost per patient vs peers
$3,159 vs $3,933 avg
-24%
Brand preference vs peers
38.7% vs 51.2% avg
Brand vs Generic
Brand: 13,107 claims · $5.4M
Generic: 20,742 claims · $365K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Insulin Lispro | 818 | $653K |
| Dapagliflozin Propanediol | 648 | $510K |
| Insulin Glargine,hum.Rec.Anlog | 715 | $370K |
| Levothyroxine Sodium | 4,705 | $355K |
| Insulin Lispro | 559 | $339K |
| Insulin Glargine,hum.Rec.Anlog | 361 | $305K |
| Dulaglutide | 298 | $295K |
| Insulin Glargine/Lixisenatide | 301 | $292K |
| Insulin Glargine,hum.Rec.Anlog | 585 | $253K |
| Insulin Lispro | 357 | $238K |
| Empagliflozin | 233 | $181K |
| Linagliptin | 197 | $130K |
| Dapaglifloz Propaned/Metformin | 160 | $126K |
| Insulin Regular, Human | 56 | $107K |
| Insulin Lispro Protamin/Lispro | 136 | $88K |
Prescribing Profile
Patient Profile
72
Avg Age
69%
Female
2.08
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data